Items where authors include "Bliss, JM"

Article

Bundred, N, Porta, N, Brunt, AM et al. (20 more authors) (2022) Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical Cancer Research. ISSN 1078-0432

Cheang, MCU, Bliss, JM, Viale, G et al. (12 more authors) (2018) Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. Breast Cancer Research and Treatment, 168 (1). pp. 169-178. ISSN 0167-6806

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Alberro, JA, Ballester, B et al. (596 more authors) (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology, 19 (1). pp. 27-39. ISSN 1470-2045

Morden, JP, Alvarez, I, Bertelli, G et al. (18 more authors) (2017) Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of Clinical Oncology, 35 (22). pp. 2507-2514. ISSN 0732-183X

Cameron, D, Morden, JP, Canney, P et al. (21 more authors) (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). pp. 929-945. ISSN 1470-2045

Speirs, V, Viale, G, Mousa, K et al. (14 more authors) (2015) Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES) - first results from PathIES. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. ISSN 0923-7534

Pinhel, I, Hills, M, Drury, S et al. (27 more authors) (2012) ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Research, 14 (2). R46. ISSN 1465-5411

Lakhani, S, Selby, P, Bliss, JM et al. (3 more authors) (1990) Chemotherapy for malignant melanoma: Combinations and high doses produce more responses without survival benefit. British Journal of Cancer, 61 (2). pp. 330-334. ISSN 0007-0920